GSK has agreed to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for $10.6 billion. GSK will assume Nuvalent’s existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
S&C represented Deerfield, Nuvalent’s largest stockholder, on the transaction.
The S&C team advising Deerfield includes Eric Krautheimer, Ari Blaut, Alan Fishman, Bradley King and Rachel Yu.